Simple exploration of 1,4-Di-Boc-piperazine-2-carboxylic acid

The synthetic route of 181955-79-3 has been constantly updated, and we look forward to future research findings.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.181955-79-3,1,4-Di-Boc-piperazine-2-carboxylic acid,as a common compound, the synthetic route is as follows.

1,4-Di(tert-butoxycarbonyl)piperazine-2-carboxylic acid (14 g, 42.37 mmol) was sequentially added to a dry reaction flask.Potassium carbonate (11.7 g, 84.7 mmol),Acetone (200mL),Methyl iodide (5.3 mL, 85 mmol),Stir at room temperature for 12 h.Filtration, the filtrate was evaporated under reduced pressure, and the residue was diluted with EA (200 mL) and water (200 mL), and the organic phase was washed with saturated brine.Dry, dry anhydrous sodium sulfate, concentrated under reduced pressure,The title compound was obtained as a white solid (13.55 g, 93%)., 181955-79-3

The synthetic route of 181955-79-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Guangdong Dongyangguang Pharmaceutical Co., Ltd.; Liu Xinchang; Ren Qingyun; Yan Guanghua; S ¡¤geerdeman; Zhang Yingjun; (200 pag.)CN109678859; (2019); A;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

Some tips on 181955-79-3

181955-79-3, The synthetic route of 181955-79-3 has been constantly updated, and we look forward to future research findings.

181955-79-3, 1,4-Di-Boc-piperazine-2-carboxylic acid is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of 1,4-bis(tert-butoxycarbonyl)piperazine-2-carboxylic acid (4.88 g, 14.7 mmol) in DMF (49 mL) was added K2CO3 (2.65 g, 19.2 mmol), and the mixture cooled to 0 C. To the mixture was then slowly added methyl iodide (1.38 mL, 22.1 mmol). The reaction stirred was stirred at room temperature for 18 hours and quenched with saturated aqueous NH4Cl (100 mL). The mixture was diluted with water and extracted with EtOAc twice. The combined organic layers were washed with water and brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography on SiO2 (Hex:EtOAc=7:1 to 5:1 to 3:1) to afford 1,4-di-tert-butyl 2-methyl piperazine-1,2,4-tricarboxylate (5.09 g, 100%) as a pale brown viscous oil. 1H-NMR (CDCl3, Varian, 400 MHz): delta 1.44 (18H, s), 2.80 (1H, br. s), 3.12-3.24 (1H, m), 3.21 (1H, br. s), 3.74 (3H, s), 3.80-4.10 (2H, m), 4.48-4.73 (2H, m).

181955-79-3, The synthetic route of 181955-79-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; HANDOK INC.; CMG Pharmaceutical Co., Ltd.; Kim, Moonsoo; Lee, Chaewoon; Lee, Gilnam; Yoon, Cheolhwan; Seo, Jeongbeob; Kim, Jay Hak; Lee, Minwoo; Jeong, Hankyul; Choi, Hyang; Jung, Myung Eun; Lee, Ki Nam; Kim, Hyun Jung; Kim, Hye Kyoung; Lee, Jae Il; Lee, MinWoo; Kim, Misoon; Choi, Soongyu; (124 pag.)US2016/168156; (2016); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

Analyzing the synthesis route of 181955-79-3

181955-79-3, As the paragraph descriping shows that 181955-79-3 is playing an increasingly important role.

181955-79-3, 1,4-Di-Boc-piperazine-2-carboxylic acid is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a dry flask were added 1, 4-di (tert-butoxycarbonyl) piperazine-2-carboxylic acid (14 g, 42.37 mmol) , potassium carbonate (11.7 g, 84.7 mmol) , acetone (200 mL) , iodomethane (5.3 mL, 85 mmol) in turn, the mixture was stirred at rt for 12 hours. The mixture was filtered, the filtrate was concentrated in vacuo and to the residue was added (200 mL) and water (200 mL) , the mixture was separated into layers, the organic layer was washed with saturated aqueous NaCl and dried over anhydrous sodium sulfate, then concentrated in vacuo to get the title compound as a white solid (13.55 g, 93%) . MS (ESI, pos. ion) m/z: 367.2 [M+Na] +.

181955-79-3, As the paragraph descriping shows that 181955-79-3 is playing an increasingly important role.

Reference£º
Patent; SUNSHINE LAKE PHARMA CO., LTD.; LIU, Xinchang; REN, Qingyun; YAN, Guanghua; GOLDMANN, Siegfried; ZHANG, Yingjun; (253 pag.)WO2019/76310; (2019); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

Brief introduction of 181955-79-3

As the paragraph descriping shows that 181955-79-3 is playing an increasingly important role.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.181955-79-3,1,4-Di-Boc-piperazine-2-carboxylic acid,as a common compound, the synthetic route is as follows.

To a dichloromethane (DCM, 40 ml) solution of Boc-protected acid (5.01 g, 15.18 mmol) as prepared in step-1 is added a solution of N-hydroxysuccinimide (1.75 g, 15.21 mmol) in THF (20ml) and a solution of DCC (3.6 g, 17.47 mmol) in DCM (20 ml) at 0 C. in the order specified. Reaction mixture stirred at 0-5 C. for 4-5 hrs, filtered, filtrate washed successively with water, aqueous sodium bicarbonate solution and finally with brine. Organic layer dried (Na2SO4) evaporated in vacuo to give the product as white solid. (Yield 5.8 g, 86.05%)., 181955-79-3

As the paragraph descriping shows that 181955-79-3 is playing an increasingly important role.

Reference£º
Patent; TORRENT PHARMACEUTICALS LTD.; US2003/225102; (2003); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

Downstream synthetic route of 181955-79-3

181955-79-3 1,4-Di-Boc-piperazine-2-carboxylic acid 11255979, apiperazines compound, is more and more widely used in various fields.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.181955-79-3,1,4-Di-Boc-piperazine-2-carboxylic acid,as a common compound, the synthetic route is as follows.

181955-79-3, Step 2-Formation of methyl 1,4-di-tert-butoxycarbonyl piperazine-2-(R)-carboxylate. 1,4-Di-tert-butoxycarbonylpiperazine-2-(R)-carboxylic acid (70 g, 212 mmol) was dissolved in acetonitrile (1.3 L). Cs2CO3 (110 g, 340 mmol) was added and the mixture stirred for 30 minutes at room temperature before the addition of methyl iodide (28 ml, 450 mmol). The reaction mixture was stirred at room temperature overnight, solids were filtered and the filtrate concentrated in vacuo. The resulting oil was dissolved in EtOAc and any insoluble material filtered. The filtrate was concentrated in vacuo to give methyl 1,4-di-tert-butoxycarbonylpiperazine-2-(R)-carboxylate (69 g, 95%). LC/MS Calcd for [M+H]+ 345.2. found 145.1 (-Boc X 2). Step 3-Formation of methyl piperazine-2-(R)-carboxylate dihydrochloride.

181955-79-3 1,4-Di-Boc-piperazine-2-carboxylic acid 11255979, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; SYMPHONY EVOLUTION, INC.; US2011/82114; (2011); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

Some tips on 181955-79-3

181955-79-3, The synthetic route of 181955-79-3 has been constantly updated, and we look forward to future research findings.

181955-79-3, 1,4-Di-Boc-piperazine-2-carboxylic acid is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Step O:1,4-di-tert-butyl 2-methyl iperazine-l,2,4-tricarboxylate (26; Rb=Me). To a mixture of 1 ,4- bis(ieri-butoxycarbonyl)-piperazine-2-carboxylic acid (25; 3.6 g, 1 1 mmol) in DMF (10 mL) was added K2C03 (2 g, 18 mmol). The resulting suspension was cooled to 0C and treated with iodomethane (1.5 mL, 12 mmol). The mixture was then allowed to warm to room temperature, stirred for 6 hours. After quenched with water (200 mL), the mixture was extracted with ethyl acetate (100 mL), and the organic layer was washed with brine, dried over anhy. Na2SC>4, filtered, and concentrated in vacuo to afford 3.6 g of the title compound as a white solid.

181955-79-3, The synthetic route of 181955-79-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; AGIOS PHARMACEUTICALS, INC.; CAO, Sheldon; POPOVICI-MULLER, Janeta; SALITURO, Francesco G.; SAUNDERS, Jeffrey; TAN, Xuefei; TRAVINS, Jeremy; YAN, Shunqi; YE, Zhixiong; WO2012/171506; (2012); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics